VivoPower Analyst Price Targets

Wall Street analyst price targets and consensus rating for VivoPower (VIVO).

Price Target Range — 1 Quarters

Analyst Consensus — 1 Analysts

1Buy

Consensus RatingOutperform# Analysts1Avg. Consensus PT$10Upside to Avg. PT+336.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

すべての評価を見る →

Date	Firm	Analyst	Action	Rating Change	Price Target
Jul 13, 2026	Noble Capital Markets	Michael Kupinski	Initiate	Outperform	$10

Analyst Ratings News

PRO
Noble Capital Markets Initiates Coverage On VivoPower with Outperform Rating, Announces Price Target of $10

Noble Capital Markets analyst Michael Kupinski initiates coverage on VivoPower (NASDAQ:VIVO) with a Outperform rating and announces Price Target of $10.

Benzinga Newsdesk

Benzinga's Top Ratings Upgrades, Downgrades For July 8, 2022

Benzinga Insights

PRO
HC Wainwright & Co. Downgrades Meridian Bioscience to Neutral, Raises Price Target to $34

HC Wainwright & Co. analyst Yi Chen downgrades Meridian Bioscience (NASDAQ:VIVO) from Buy to Neutral and raises the price target from $30 to $34.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Meridian Bioscience, Raises Price Target to $30

HC Wainwright & Co. analyst Yi Chen maintains Meridian Bioscience (NASDAQ:VIVO) with a Buy and raises the price target from $28 to $30.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Meridian Bioscience, Raises Price Target to $28

HC Wainwright & Co. analyst Yi Chen maintains Meridian Bioscience (NASDAQ:VIVO) with a Buy and raises the price target from $27 to $28.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Meridian Bioscience, Lowers Price Target to $27

HC Wainwright & Co. analyst Yi Chen maintains Meridian Bioscience (NASDAQ:VIVO) with a Buy and lowers the price target from $30 to $27.

Benzinga Newsdesk

VivoPower PLC

ニュース

パートナーシップ

ベンジンガ・グローバル

VivoPower Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Noble Capital Markets Initiates Coverage On VivoPower with Outperform Rating, Announces Price Target of $10

Benzinga's Top Ratings Upgrades, Downgrades For July 8, 2022

PRO
HC Wainwright & Co. Downgrades Meridian Bioscience to Neutral, Raises Price Target to $34

PRO
HC Wainwright & Co. Maintains Buy on Meridian Bioscience, Raises Price Target to $30

PRO
HC Wainwright & Co. Maintains Buy on Meridian Bioscience, Raises Price Target to $28

PRO
HC Wainwright & Co. Maintains Buy on Meridian Bioscience, Lowers Price Target to $27

People Also Watch

People Also Watch

VivoPower PLC

ニュース

パートナーシップ

ベンジンガ・グローバル

VivoPower Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRONoble Capital Markets Initiates Coverage On VivoPower with Outperform Rating, Announces Price Target of $10

Benzinga's Top Ratings Upgrades, Downgrades For July 8, 2022

PROHC Wainwright & Co. Downgrades Meridian Bioscience to Neutral, Raises Price Target to $34

PROHC Wainwright & Co. Maintains Buy on Meridian Bioscience, Raises Price Target to $30

PROHC Wainwright & Co. Maintains Buy on Meridian Bioscience, Raises Price Target to $28

PROHC Wainwright & Co. Maintains Buy on Meridian Bioscience, Lowers Price Target to $27

People Also Watch

People Also Watch

PRO
Noble Capital Markets Initiates Coverage On VivoPower with Outperform Rating, Announces Price Target of $10

PRO
HC Wainwright & Co. Downgrades Meridian Bioscience to Neutral, Raises Price Target to $34

PRO
HC Wainwright & Co. Maintains Buy on Meridian Bioscience, Raises Price Target to $30

PRO
HC Wainwright & Co. Maintains Buy on Meridian Bioscience, Raises Price Target to $28

PRO
HC Wainwright & Co. Maintains Buy on Meridian Bioscience, Lowers Price Target to $27